ZURA BIO LIMITED (ZURA) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Win.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Win.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Win.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Win.
10/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 7 wins, 5 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
LoseZURA / S&P -0.84% / 15.20% |
LoseZURA / S&P ZURA unavailable / 15.00% |
WinZURA / S&P 61.43% / 50.40% |
| 2026-Q12/3 |
WinZURA / S&P 13.55% / -4.33% |
LoseZURA / S&P ZURA unavailable / 11.30% |
WinZURA / S&P 55.71% / 27.70% |
| 2025-Q42/3 |
WinZURA / S&P 21.02% / 2.65% |
LoseZURA / S&P ZURA unavailable / 9.00% |
WinZURA / S&P 100.00% / 13.40% |
| 2025-Q32/3 |
WinZURA / S&P 312.38% / 8.12% |
LoseZURA / S&P ZURA unavailable / 4.61% |
WinZURA / S&P 103.13% / 13.45% |
| 2025-Q21/3 |
LoseZURA / S&P -18.60% / 10.94% |
LoseZURA / S&P ZURA unavailable / 4.83% |
WinZURA / S&P 191.67% / 10.63% |
| 2025-Q10/3 |
LoseZURA / S&P -48.40% / -4.27% |
LoseZURA / S&P ZURA unavailable / 4.98% |
LoseZURA / S&P -49.28% / 10.57% |
| 2024-Q40/3 |
LoseZURA / S&P -38.42% / 2.41% |
LoseZURA / S&P ZURA unavailable / 5.25% |
LoseZURA / S&P -87.14% / 6.15% |
| 2024-Q31/3 |
WinZURA / S&P 16.00% / 5.89% |
LoseZURA / S&P ZURA unavailable / 5.89% |
LoseZURA / S&P -99.64% / 6.11% |
| 2024-Q21/3 |
WinZURA / S&P 36.19% / 4.28% |
LoseZURA / S&P ZURA unavailable / 5.38% |
LoseZURA / S&P -99.74% / 5.12% |
| 2024-Q10/3 |
LoseZURA / S&P -44.97% / 10.56% |
LoseZURA / S&P ZURA unavailable / 5.71% |
LoseZURA / S&P -98.62% / 5.59% |
| 2023-Q40/3 |
LoseZURA / S&P -29.24% / 11.69% |
LoseZURA / S&P ZURA unavailable / 6.81% |
LoseZURA / S&P -99.99% / 7.78% |
| 2023-Q30/3 |
LoseZURA / S&P -19.51% / -3.27% |
LoseZURA / S&P ZURA unavailable / 7.52% |
LoseZURA / S&P ZURA unavailable / -5.03% |
| 2023-Q20/3 |
LoseZURA / S&P -45.04% / 8.74% |
LoseZURA / S&P ZURA unavailable / 9.50% |
LoseZURA / S&P ZURA unavailable / -8.57% |
| 2023-Q10/3 |
LoseZURA / S&P ZURA unavailable / 7.50% |
LoseZURA / S&P ZURA unavailable / 10.77% |
LoseZURA / S&P ZURA unavailable / -15.69% |
| 2022-Q40/3 |
LoseZURA / S&P ZURA unavailable / 7.56% |
LoseZURA / S&P ZURA unavailable / 11.88% |
LoseZURA / S&P ZURA unavailable / -17.99% |
| 2022-Q30/3 |
LoseZURA / S&P ZURA unavailable / -4.88% |
LoseZURA / S&P ZURA unavailable / 13.47% |
LoseZURA / S&P ZURA unavailable / -1.41% |
| 2022-Q20/3 |
LoseZURA / S&P ZURA unavailable / -16.10% |
LoseZURA / S&P ZURA unavailable / 13.71% |
LoseZURA / S&P ZURA unavailable / 11.04% |
| 2022-Q10/3 |
LoseZURA / S&P ZURA unavailable / -4.60% |
LoseZURA / S&P ZURA unavailable / 15.97% |
LoseZURA / S&P ZURA unavailable / 42.23% |
| 2021-Q40/3 |
LoseZURA / S&P ZURA unavailable / 11.03% |
LoseZURA / S&P ZURA unavailable / 15.00% |
LoseZURA / S&P ZURA unavailable / 96.40% |
| 2021-Q30/3 |
LoseZURA / S&P ZURA unavailable / 0.58% |
LoseZURA / S&P ZURA unavailable / 10.77% |
LoseZURA / S&P ZURA unavailable / 69.42% |
| 2021-Q20/3 |
LoseZURA / S&P ZURA unavailable / 8.55% |
LoseZURA / S&P ZURA unavailable / 6.58% |
LoseZURA / S&P ZURA unavailable / 51.81% |
| 2021-Q10/3 |
LoseZURA / S&P ZURA unavailable / 6.17% |
LoseZURA / S&P ZURA unavailable / -1.06% |
LoseZURA / S&P ZURA unavailable / 7.39% |
| 2020-Q40/3 |
LoseZURA / S&P ZURA unavailable / 12.15% |
LoseZURA / S&P ZURA unavailable / -3.72% |
LoseZURA / S&P ZURA unavailable / -33.42% |
| 2020-Q30/3 |
LoseZURA / S&P ZURA unavailable / 8.93% |
LoseZURA / S&P ZURA unavailable / -2.04% |
LoseZURA / S&P ZURA unavailable / -27.10% |
| 2020-Q20/3 |
LoseZURA / S&P ZURA unavailable / 20.54% |
LoseZURA / S&P ZURA unavailable / -0.46% |
LoseZURA / S&P ZURA unavailable / -27.11% |
| 2020-Q10/3 |
LoseZURA / S&P ZURA unavailable / -19.60% |
LoseZURA / S&P ZURA unavailable / 3.47% |
LoseZURA / S&P ZURA unavailable / -14.75% |
| 2019-Q40/3 |
LoseZURA / S&P ZURA unavailable / 9.07% |
LoseZURA / S&P ZURA unavailable / 5.36% |
LoseZURA / S&P ZURA unavailable / 2.99% |
| 2019-Q30/3 |
LoseZURA / S&P ZURA unavailable / 1.70% |
LoseZURA / S&P ZURA unavailable / 5.02% |
LoseZURA / S&P ZURA unavailable / 0.21% |
| 2019-Q20/3 |
LoseZURA / S&P ZURA unavailable / 4.30% |
LoseZURA / S&P ZURA unavailable / 6.64% |
LoseZURA / S&P ZURA unavailable / 8.65% |
| 2019-Q10/3 |
LoseZURA / S&P ZURA unavailable / 13.65% |
LoseZURA / S&P ZURA unavailable / 8.12% |
LoseZURA / S&P ZURA unavailable / 14.29% |
| 2018-Q40/3 |
LoseZURA / S&P ZURA unavailable / -13.52% |
LoseZURA / S&P ZURA unavailable / 9.05% |
LoseZURA / S&P ZURA unavailable / 18.23% |
| 2018-Q30/3 |
LoseZURA / S&P ZURA unavailable / 7.71% |
LoseZURA / S&P ZURA unavailable / 10.21% |
LoseZURA / S&P ZURA unavailable / 19.06% |
| 2018-Q20/3 |
LoseZURA / S&P ZURA unavailable / 3.43% |
LoseZURA / S&P ZURA unavailable / 9.03% |
LoseZURA / S&P ZURA unavailable / 14.46% |
| 2018-Q10/3 |
LoseZURA / S&P ZURA unavailable / -0.76% |
LoseZURA / S&P ZURA unavailable / 7.68% |
LoseZURA / S&P ZURA unavailable / 12.46% |
| 2017-Q40/3 |
LoseZURA / S&P ZURA unavailable / 6.64% |
LoseZURA / S&P ZURA unavailable / 7.03% |
LoseZURA / S&P ZURA unavailable / 13.82% |
| 2017-Q30/3 |
LoseZURA / S&P ZURA unavailable / 4.48% |
LoseZURA / S&P ZURA unavailable / 5.68% |
LoseZURA / S&P ZURA unavailable / 17.57% |
| 2017-Q20/3 |
LoseZURA / S&P ZURA unavailable / 3.09% |
LoseZURA / S&P ZURA unavailable / 4.83% |
LoseZURA / S&P ZURA unavailable / 17.74% |
| 2017-Q10/3 |
LoseZURA / S&P ZURA unavailable / 6.07% |
LoseZURA / S&P ZURA unavailable / 3.67% |
LoseZURA / S&P ZURA unavailable / 13.32% |
| 2016-Q40/3 |
LoseZURA / S&P ZURA unavailable / 3.82% |
LoseZURA / S&P ZURA unavailable / 2.09% |
LoseZURA / S&P ZURA unavailable / 7.05% |
| 2016-Q30/3 |
LoseZURA / S&P ZURA unavailable / 3.85% |
LoseZURA / S&P ZURA unavailable / 0.20% |
LoseZURA / S&P ZURA unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | ZURA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 186.76% | 20.78% |
| Annualized return | 186.76% | 20.78% |
5Y · 2023-03-21 to 2026-08-27
| Metric | ZURA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -19.20% | 83.14% |
| Annualized return | -4.17% | 12.86% |
10Y · 2023-03-21 to 2026-08-27
| Metric | ZURA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -19.20% | 319.30% |
| Annualized return | -2.11% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |